Abstract: Cancer is the second leading cause of mortality worldwide despite tremendous advances in treatment. The promise of precision oncology...
Better Medicines Through Signaling Dynamics
13
Years in business
2
Therapeutic Areas
46
Publications
Immuneering’s novel drug candidates spare healthy normal cells by modulating signaling dynamics to focus therapeutic impact against tumor cells.
Platform
Immuneering’s innovative R&D platform has a long history of reproducibly identifying drug targets, pinpointing biomarkers, stratifying patients and elucidating drug mechanisms of action. Currently, our platform is employed to drive Immuneering’s internal pipeline and those of our high value R&D relationships with select partners.
Publications
Our commitment to rigor and reproducible data analysis is validated by a long track record of peer-reviewed publications. In collaboration with our partners in pharma and the scientific community, our research has been featured in a number of high-impact journals.
Publications
Reporting guidelines for human microbiome research: the STORMS checklist
The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics,...
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
Despite an increasing demand for precision medicine enabled by NGS measurement of actionable mutations in circulating tumor DNA (ctDNA)...
Orchestrating and sharing large multimodal data for transparent and reproducible research
Reproducibility is essential to open science, as there is limited relevance for findings that can not be reproduced by...
The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance...
Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing
Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each...
Introduction: Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on...
A primer on applying AI synergistically with domain expertise to oncology
Abstract Background The concurrent growth of large-scale oncology data alongside the computational methods with which to analyze and model...
Oncopanel genomic testing, which identifies important somatic variants, is increasingly common in medical practice and especially in clinical trials....
Background Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing...
